Vinay Prasad has regained chief medical and scientific officer roles at the FDA’s Center for Biologics Evaluation and Research. Meanwhile, the FDA denies reports about abandoning some advisory committee meetings. Industry observers note evolving regulatory dynamics amid growing focus on efficient drug approvals. Additionally, regulatory snapshots and clinical trial updates highlight ongoing global submissions and approvals impacting biopharma development.